29 matches for your search in the start-up spotlight
rss
Her start-up Baxiva is developing a vaccine that makes bacteria visible to the immune system
03-Feb-2025
Every second woman and every eighth man suffer from urinary tract infections. These are painful and can recur with serious health consequences. Pioneer Fellow Giorgia Greter has a solution. Giorgia Greter could have been sitting in one of these minimalist, but elegant offices of a venture capital ...
Innovative vaccine based on virus-like particles
18-Dec-2024
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, ...
Verovaccines leverages its new capabilities for rapid emergency response and cost-effective classical animal health vaccine development
09-Oct-2024
The German vaccine specialist Verovaccines has shown how to go from a simple BTV-3 virus sequence to a validated vaccine in just a few months. In addition, an approval dossier has been created, which is now around 90% complete. The company expects to receive emergency use authorization before the ...
Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines
30-Sep-2024
Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, announces a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding ...
Another milestone reached: researchers work together with Swiss biotech start-up to further develop the vaccine
29-Feb-2024
Rocketvax AG, together with the German Research Foundation (DFG), has financially supported a study carried out as part of a joint project of the Swiss National Science Foundation (SNSF, National Research Program “Covid-19,” NRP 78) and the German Research Foundation (DFG) “Recoding the ...
New European and US investors: Nouscom Raises €67.5 million in Oversubscribed Series C Financing Round
15-Nov-2023
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned ...
2.5 million euros for five research teams from Bavaria
26-Oct-2023
The five winners of this year's m4 Award pre-founding competition have been announced. Each winning team will receive 500,000 euros for their project to solve urgent medical challenges. The award was announced by BioM together with the Bavarian State Ministry of Economic Affairs, Regional ...
Core Facility Animal Models and start-up company Iguana cooperate
17-Oct-2023
The Core Facility Animal Models (CAM) announces a new collaboration with drug discovery start-up Iguana Biotechnology GmbH (Iguana) to test their innovative vaccine candidate against Helicobacter pylori. Helicobacter pylori is one of the most common infectious diseases worldwide. It is a ...
New vaccine technology could protect from future Coronaviruses and variants
05-Oct-2023
Studies of a ‘future-proof’ vaccine antigen candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals, suggesting that a single vaccine with combinations of these novel antigens could protect against an even greater range of current and ...
Verovacines completes the validation of its vaccine and manufacturing platforms
13-Jul-2023
For the German vaccine specialist Verovaccines, all technological prerequisites are now in place to enter a new phase of the company’s development. During the validation phase both technology platforms have been significantly de-risked: The Unified Vaccine Platform has been validated in vivo ...
